<DOC>
	<DOCNO>NCT02238184</DOCNO>
	<brief_summary>To obtain information prescribe pattern therapeutic long term value patient suffer moderate severs Chronic Obstructive Pulmonary Disease condition daily practice</brief_summary>
	<brief_title>Postmarketing Surveillance Study Anticholinergics - Prescribing Pattern Therapeutic Long Term Value Patients Suffering From Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Cholinergic Antagonists</mesh_term>
	<mesh_term>Oxitropium</mesh_term>
	<criteria>Patients gender older 40 year , suffer moderate severe Chronic Obstructive Pulmonary Disease Only patient show follow diagnosis parameter consider inclusion FEV1 ( Forced expiratory volume 1 second ) FEV1/VC ( vital capacity ) &lt; 70 % Reversibility FEV1 &lt; 12 % last 6 month Smoker Exsmoker ( &gt; 10 Pack year ) Asthma exclude â€¢ Contraindications list Instructions Use/Summary Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>